3D Medicines Inc. (HKG:1244)

Market Cap	1.45B
Revenue (ttm)	474.25M
Net Income (ttm)	-194.38M
Shares Out	244.97M
EPS (ttm)	-0.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	370,500
Average Volume	416,577
Open	5.99
Previous Close	5.99
Day's Range	5.85 - 6.00
52-Week Range	1.60 - 6.18
Beta	0.85
RSI	78.78
Earnings Date	Aug 25, 2025

About 3D Medicines

3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and other drug candidates for the treatment of patients with various cancers in the People’s Republic of China. The company offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. It is also developing Envafolimab, which is in Phase III clinical trials for advanced BTC and NSCLC; and in P...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 191
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1244

Financial Performance

In 2024, 3D Medicines's revenue was 445.65 million, a decrease of -29.81% compared to the previous year's 634.95 million. Losses were -182.66 million, -65.19% less than in 2023.

Financial numbers in CNY